

THE
EXCHANGE ASIA

Tabung Haji Becomes Major Shareholder In Duopharma

March 4, 2026

Lembaga Tabung Haji has become a substantial shareholder in Duopharma Biotech Bhd following its latest acquisition of shares in the pharmaceutical company.

According to a filing with Bursa Malaysia on Tuesday, the pilgrimage fund crossed the 5% disclosure threshold after purchasing 500,000 shares, representing a 0.052% stake, on Monday. The acquisition raised Tabung Haji's total shareholding in Duopharma to 5.046%, equivalent to approximately 48.54 million shares.



Lembaga Tabung Haji has emerged as a substantial shareholder of Duopharma Biotech Bhd after acquiring 500,000 shares on Monday, bringing its total stake to 5.046%, representing 48.54 million shares.

With this development, Tabung Haji joins the list of key institutional shareholders in Duopharma. Permodalan Nasional Bhd (PNB) remains the company's largest shareholder with a 44.104% stake, while the Employees Provident Fund (EPF) holds 9.087%.

The move reflects Tabung Haji's continued strategy of building strategic positions in established Malaysian companies across various sectors. Last month, the fund re-emerged as a substantial shareholder in electronic manufacturing services provider SKP Resources Bhd with a 5.092% stake after being absent from the company's share register for nearly a decade.

In addition, Tabung Haji recently acquired significant stakes in newly listed tanker operator Orkim Bhd, where it holds 5.006%, and retailer AEON Co (M) Bhd, with a 5.013% stake. These investments signal a broader diversification effort across healthcare, manufacturing, logistics, and retail sectors.

Duopharma shares closed three sen, or 2.07%, higher at RM1.48 on Tuesday, giving the group a market capitalisation of approximately RM1.42 billion. The stock has risen more than 19% over the past year, reflecting improved investor sentiment and steady performance in the healthcare sector.

Tabung Haji's latest acquisition further strengthens its presence in Malaysia's capital markets, positioning the fund as an increasingly active institutional investor in publicly listed companies.